Introduction
============

The emergence of MDR *Enterobacteriaceae* and the lack of new antibiotics coming to market to combat them bring us perilously to the end of the "Antibiotic era." Among *Enterobacteriaceae, Klebsiella pneumoniae*, is found to be associated with the highest rates of carbapenem resistance ([@B16]). Polymyxin antibiotics such as colistin are among the few antimicrobial agents that retain activity against MDR-GNB in particular CRE and often considered as the last-line therapy to treat infections caused by these superbugs ([@B13]; [@B19]). Polymyxins (polymyxin B and colistin) are cationic antimicrobial peptides that target anionic lipid A phosphate moiety of bacterial LPS causing membrane leakage and eventually cell death ([@B11]; [@B9]). Bacteria employ several means to protect themselves from antimicrobial activity of polymyxins. The most common resistance mechanism in *Enterobacteriaceae* is attributed to the covalent modifications of the lipid A moiety of LPS through the incorporation of positively charged groups such as PEtN and [L]{.smallcaps}-Ara4N. These modifications neutralize the negative charges of LPS and subsequently reduce binding affinity of colistin to its target ([@B22]). LPS modification in *K. pneumoniae* is mediated by the activation of PmrA/PmrB two-component regulatory system (TCRS) which regulates expression of the genes located in *pmrCAB* and *pmrHFIJKLM* operons encoding for enzymes implicated in the LPS modifications. Moreover, a second TCRS, PhoP/PhoQ is known to contribute to polymyxin resistance by indirectly activating the PmrA/PmrB TCRS via PmrD linker protein. Mutations in these TCRSs can cause constitutive expression of the *pmrCAB* and *pmrHFIJKLM* operons and consequently transfer of PEtN and [L]{.smallcaps}-Ara4N, respectively, to lipid A ([@B22]; [@B19]). Moreover, inactivation of the PhoQ/PhoP negative regulator encoded by *mgrB* gene has been identified to play a prominent role in polymyxin resistance in *K. pneumoniae* isolates ([@B4]; [@B19]; [@B20]). Genetic alterations such as Leu26Pro in PhoQ ([@B7]), Leu82Arg ([@B3]), and Thr157Pro ([@B12]) in PmrB, Q30stop, C28stop and insertion of IS elements in MgrB ([@B20]) have been found to contribute to colistin resistance in *K. pneumoniae* isolates. In addition to these chromosomally mediated mechanisms, plasmid-encoded colistin resistance genes, *mcr-1, mcr-2, mcr-3, and mcr-4* encoding a PEtN transferase have been recently reported as a transmissible resistance mechanism in *Enterobacteriaceae* ([@B10]; [@B15]; [@B26]; [@B5]; [@B27]). Due to lack of information about the molecular mechanisms of colistin resistance in *K. pneumoniae* isolates in Iran, we aimed to explore these mechanisms in colistin resistant *K. pneumoniae* strains from this geographic region.

Materials and Methods {#s1}
=====================

Bacterial Strains and Antimicrobial Susceptibility Testing
----------------------------------------------------------

A total of 20 col-R KP clinical strains isolated from the same number of patients hospitalized in Imam Khomeini hospital, the largest medical center of the country with 1,400 beds were studied. The isolates were obtained between 2015 and 2017 through antimicrobial resistance surveillance study for detection of col-R isolates. MICs of colistin were determined by broth macrodilution method using colistin sulfate (Sigma--Aldrich) over a range of dilutions from 0.125 to 128 μg/ml according to instructions described by [@B25] and [@B8]. Isolates characterized with MIC values greater than 2 μg/ml were categorized as resistant according to guidelines described by the European Committee on Antimicrobial Susceptibility Testing (EUCAST)^[1](#fn01){ref-type="fn"}^. *K. pneumoniae* ATCC 700603 was used as a quality control for antimicrobial susceptibility testing.

Bacterial Genotyping
--------------------

The genetic relatedness of the col-R KP isolates was assessed by pulsed-field gel electrophoresis (PFGE) analysis using *Xba*I digested genomic DNA as described previously ([@B21]) and results were interpreted as recommended by [@B23].

Molecular Characterization of Colistin Resistance
-------------------------------------------------

In order to investigate the possible contribution of plasmid encoded *mcr-1, mcr-2, mcr-3*, and *mcr-4* genes in resistance development, genomic DNAs were obtained from the isolates and were subjected to polymerase chain reaction (PCR) using previously described primers ([@B15]; [@B26]; [@B5]; [@B27]) (**Table [1](#T1){ref-type="table"}**). To detect any genetic alterations associated with colistin resistance, *pmrA, pmrB, phoP, phoQ*, and *mgrB* genes were amplified using primers listed in **Table [1](#T1){ref-type="table"}**. The resulting amplicons were sent to SEQLAB Sequence Laboratories (Göttingen GmbH, Germany) for sequencing. Genomic DNA from *K. pneumoniae* ATCC 700603 and three other col-S *K. pneumoniae* clinical isolates were used as control.

###### 

Nucleotide sequences of primers used in this study.

  Primer name   Sequence (5′ to 3′)      Size of product (bp)   Reference
  ------------- ------------------------ ---------------------- ------------
  Sequencing                                                    
  pmrA-F        CGCAGGATAATCTGTTCTCCA    808                    This study
  pmrA-R        GGTCCAGGTTTCAGTTGCAA                            
  pmrB-F1       GCGAAAAGATTGGCAAATCG     659                    This study
  pmrB-R1       GGAAATGCTGGTGGTCATCTGA                          
  pmrB-F2       CCCTGAATCAGTTGGTTTC      714                    This study
  pmrB-R2       ATCAATGGGTGCTGACGTT                             
  mgrB-F        ACCACCTCAAAGAGAAGGCGTT   347                    This study
  mgrB-R        GGCGTGATTTTGACACGAACAC                          
  phoP-F        GAGCGTCAGACTACTATCGA     912                    This study
  phoP-R        GTTTTCCCATCTCGCCAGCA                            
  phoQ-F        CCACAGGACGTCATCACCA      1,594                  This study
  phoQ-R        GCAGGTGTCTGACAGGGATT                            
  mcr-1-F       CGGTCAGTCCGTTTGTTC       309                    [@B15]
  mcr-1-R       CTTGGTCGGTCTGTAGGG                              
  mcr-2-F       TGTTGCTTGTGCCGATTGGA     567                    [@B26]
  mcr-2-R       AGATGGTATTGTTGGTTGCTG                           
  mcr-3-F       TTGGCACTGTATTTTGCATTT    542                    [@B27]
  mcr-3-R       TTAACGAAATTGGCTGGAACA                           
  mcr-4-F       ATTGGGATAGTCGCCTTTTT     487                    [@B5]
  mcr-4-R       TTACAGCCAGAATCATTATCA                           
  RT-qPCR                                                       
  pmrC-F        CTCTCGCCTCGTTCCTGAA      140                    This study
  pmrC-R        CGGAGTGGTGTCGAGGATA                             
  pmrK-F        GGTGTATGCGATTGGCACCTA    132                    This study
  pmrK-R        AGCAGCACGTAGCCCAGTAT                            
  rpsl-F        CCGTGGCGGTCGTGTTAAAGA    109                    [@B2]
  rpsl-R        GCCGTACTTGGAGCGAGCCTG                           
  mgrB-ext-F    AAGGCGTTCATTCTACCACC     253                    [@B2]
  mgrB-ext-R    TTAAGAAGGCCGTGCTATCC                            
  pmrB-ext-F    ACCTACGCGAAAAGATTGGC     1,274                  [@B12]
  pmrB-ext-R    GATGAGGATAGCGCCCATGC                            

Transcriptional Analysis of *pmrK* and *pmrC* by RT-qPCR
--------------------------------------------------------

To investigate whether colistin resistance is associated with upregulation of *pmrCAB* and *pmrHFIJKLM* operons, the expression level of genes encoding for LPS modifying enzymes including the *pmrK* (encoding for [L]{.smallcaps}-Ara4N transferase) and the *pmrC* (encoding for PEtN transferase) was evaluated. To this end, three col-S and 20 col-R KP isolates were grown to the mid-logarithmic phase of growth in LB broth medium and cells were harvested at an optical density of 1 at 600 nm (OD600). Bacterial cell wall was broken by several freeze/thaw cycles and total RNA was extracted using a GeneAll RiboEx Total RNA extraction kit (GeneAll Biotechnology, Seoul, South Korea). To remove genomic DNA contamination, total RNA was digested by RNase-free DNase I (Takara Biotechnology, Dalian, China) and then purified according to the manufacturer's instructions. First-strand cDNA was synthesized from 1 μg of total RNA using Revert Aid first strand cDNA synthesis kit (Thermo Scientific). Real-time PCR amplification was performed using a Power SYBR green PCR master mix (Applied Biosystems) on a Eco Real-Time PCR system (Illumina) under the following conditions: 1 cycle of 95°C for 10 min, 45 cycles of 95°C for 15 s, 60°C for 30 s and 72°C for 25 s. Melt curve analyses were performed after each run to ensure single amplicon production. The Relative gene expression levels were calculated using the 2^-ΔΔC~T~^ formula with *rpsL* gene as internal control. Oligonucleotide sequences used for amplification of *pmrK, pmrC*, and *rpsL* fragments are listed in **Table [1](#T1){ref-type="table"}**.

Complementation Assays
----------------------

To determine whether alterations in the *pmrB* and *mgrB* were mediating colistin resistance, complementation assay was performed. The full length *mgrB* and *pmrB* genes from a col-S KP isolate were amplified by PCR using primers pmrB-ext-F, pmrB-ext-R, mgrB-ext-F, and mgrB-ext-R (**Table [1](#T1){ref-type="table"}**). The amplified fragments were cloned in to pCR-Blunt II-TOPO vector by Zero blunt TOPO PCR cloning kit (Invitrogen). The authenticity of the cloned fragments was confirmed by sequencing. The resulting pTOPO-mgrB and pTOPO-pmrB plasmids were introduced in to *Escherichia coli* TOP 10 by electroporation strategy and transformants were selected by overnight incubation at Muller--Hinton agar containing 50 μg/ml kanamycin. Plasmid purification was done by QIAprep Spin Miniprep Kit (Qiagen). Extracted plasmids were separately introduced to col-R KP isolates and transformants were selected on MHA plates supplemented with 250 μg/ml of zeocin. Overnight cultures of transformed col-R KP isolates were grown in MHB supplemented with 250 μg/ml zeocin, washed and resuspended in MHB and used for colistin MIC measurement. Col-S isolate KP51 was used as control.

Nucleotide Sequence Accession Numbers
-------------------------------------

The nucleotide sequences of the wild-type *phoP, phoQ, pmrA, pmrB*, and *mgrB* genes have been deposited at GenBank nucleotide sequence database under the accession numbers [MG243705](MG243705) to [MG243721](MG243721), [MF431844](MF431844), and [MF431845](MF431845). Also nucleotide sequences of the altered *pmrB* and mutated/disrupted *mgrB* genes have been deposited under GenBank accession numbers [MF431841](MF431841) to [MF431843](MF431843) and [MF431836](MF431836) to [MF431840](MF431840), respectively.

Results
=======

Bacterial Genotyping and Molecular Determinants of Colistin Resistance
----------------------------------------------------------------------

A total of 20 col-R KP clinical isolates were studied to identify underlying resistance mechanisms. PFGE analyses divided the isolates into 17 PFGE patterns (pulsotypes) including A (KP17 and KP15), B1 (KP03), B2 (KP14), C1 (KP13), C2 (KP12), C3 (KP16), D1 (KP04), D2 (KP09), D3 (KP07), D4 (KP01), D5 (KP10), E (KP19 and KP20), F1 (KP08), F2 (KP06), G (KP05), H1 (KP02) and H2 (KP11). PFGE could not yield DNA fingerprints for isolate KP18 and therefore this isolate could not be genotyped. Isolates in types A and E were indistinguishable, and others were closely related (data not shown). To assess the role of plasmid encoded resistance genes, *mcr-1, mcr-2, mcr-3*, and *mcr-4*, PCR was carried out using genomic DNA obtained from 20 col-R, three col-S KP clinical isolates and *K. pneumoniae* ATCC 700603. *mcr* genes were not detected in any of the studied isolates indicating that chromosomally mediated mechanisms might play a prominent role in resistance occurrence. All col-R isolates revealed wild type *pmrA, phoP*, and *phoQ* genes. Fifteen col-R KP isolates (75%) exhibited alterations in the coding or putative promoter region of the *mgrB*. Two types of *mgrB* alterations were observed: premature termination due to nonsense mutations and insertion of IS elements (**Table [2](#T2){ref-type="table"}**). In isolates characterized with *mgrB* premature termination, CAG (codon 30, glutamine) and TGC (codon39, cysteine) converted to TAG and TGA, respectively, creating a premature stop codon within the coding region of *mgrB* (**Figure [1](#F1){ref-type="fig"}**). These alterations resulted in production of a truncated and most likely non-functional 29 and 38 amino acid long proteins, respectively, instead of a wild-type protein with 47 amino acids. IS elements involved in the *mgrB* disruption belonged to IS*1*-like (768 bp) and IS*5*-like families (1,056 bp) which inserted in different positions of the *mgrB* gene. While in five isolates IS elements targeted coding region of the *mgrB* (positions +70 and +120), in one isolate IS element was found to be inserted at position -60 which was located between protein start codon and putative promoter region. The latter alteration disrupted the promoter and consequently transcription of the *mgrB* gene (**Figure [1](#F1){ref-type="fig"}**). Sequence analysis of the *pmrB* gene revealed that 19 of 20 col-R KP strains (95%) had a point mutation in the coding region of the *pmrB* including Leu213Met (CTG \> ATG), Ala246Thr (GCC \> ACC), and Arg256Gly (CGC \> GGC) substitutions (**Table [2](#T2){ref-type="table"}**). All col-S KP isolates revealed a wild-type *pmrA, pmrB, mgrB, phoP*, and *phoQ* sequences.

###### 

Phenotypic and genotypic characteristics of the studied *K. pneumoniae* strains.

  Isolate   Year, ward, and source of isolation   MIC (μg/ml)   *mgrB* sequence                                                   *pmrB* sequence   Relative expression level   
  --------- ------------------------------------- ------------- ----------------------------------------------------------------- ----------------- --------------------------- -------------
  KP13      2016-Neurology-Wound                  128           Insertional inactivation by IS*1*-like (+120)                     A246T             3.83 ± 1.01                 --^a^
  KP12      2016-Emergency-Blood                  64            Insertional inactivation by IS*1*-like (+120)                     A246T             4.12 ± 0.05                 --^a^
  KP16      2016-ICU-Wound                        128           Insertional inactivation by IS*1*-like (+120)                     A246T             3.01 ± 0.02                 --^a^
  KP01      2015-ICU-Blood                        128           Premature termination by nonsense mutation at nt88                L213M             13.04 ± 0.5                 1.87 ± 0.18
  KP04      2015-ICU-Blood                        \>128         Premature termination by nonsense mutation at nt88                L213M             7.08 ± 0.25                 3.5 ± 0.07
  KP07      2015-ICU-Tracheal aspirate            \>128         Premature termination by nonsense mutation at nt88                L213M             26.91 ± 2.68                --^a^
  KP08      2016-ICU-Blood                        128           Premature termination by nonsense mutation at nt88                L213M             2.1 ± 0.77                  --^a^
  KP09      2015-SICU-Tracheal aspirate           \>128         Premature termination by nonsense mutation at nt88                L213M             34.47 ± 1.0                 9 ± 2.1
  KP10      2016-ICU-Tracheal aspirate            \>128         Premature termination by nonsense mutation at nt88                L213M             3.17 ± 0.03                 3.66 ± 1.08
  KP18      2017-Internal medicine-Blood          \>128         Premature termination by nonsense mutation at nt88                L213M             1.97 ± 0.04                 --^a^
  KP17      2016-Urology-Tracheal aspirate        128           Premature termination by nonsense mutation at nt117               A246T             3.96 ± 0.04                 --^a^
  KP15      2016-ICU-Blood                        128           premature termination by nonsense mutation at nt117               A246T             1.98 ± 0.12                 --^a^
  KP02      2015-SICU-Urine                       32            Insertional inactivation by IS*5*-like (+70)                      R256G             2.56 ± 0.14                 3.26 ± 0.2
  KP11      2016-Internal medicine-Wound          128           Insertional inactivation by IS*5*-like (+70)                      R256G             77 ± 1.50                   15.4 ± 3.9
  KP06      2016-Neurology-Tracheal aspirate      64            Insertional inactivation by IS*1*-like at promoter region (-60)   WT                11.69 ± 2.59                9.15 ± 1.5
  KP03      2015-SICU-Blood                       128           WT^b^                                                             R256G             64.36 ± 2.6                 6.9 ± 0.83
  KP05      2015-Urology-Urine                    8             WT                                                                R256G             24.3 ± 0.23                 2.79 ± 0.15
  KP14      2016-Emergency-Urine                  128           WT                                                                R256G             76.07 ± 6.2                 7.06 ± 2.1
  KP51      2016-CCU-Urine                        0.5           WT                                                                WT                --^a^                       --^a^
  KP106     2016-Outpatient clinic-Urine          0.5           WT                                                                WT                --^a^                       --^a^
  KP109     2016-Orthopedics-Urine                0.25          WT                                                                WT                --^a^                       --^a^
  KP19      2017-ICU-Blood                        128           WT                                                                A246T             2.2 ± 0.23                  1.67 ± 0.33
  KP20      2017-ICU-Blood                        128           WT                                                                A246T             2.5 ± 0.7                   1.7 ± 0.53

a

Unaltered expression levels compared to col-S isolates.

b

WT, wild-type.

![*mgrB* alterations mediated by insertion of IS elements and mutations. The arrow and open box indicate the target site for insertion of IS elements and amino acid changes, respectively.](fmicb-08-02470-g001){#F1}

Colistin Resistance Is Associated with Overexpression of Operons Encoding for LPS Modifying Proteins
----------------------------------------------------------------------------------------------------

To examine the association between colistin resistance and *pmrHFIJKLM* and *pmrCAB* expression, the transcription levels of *pmrK* and *pmrC* genes encoding proteins implicated in decoration of LPS with [L]{.smallcaps}-Ara4N and PEtN, respectively, were analyzed by RT-qPCR method. In general, all col-R KP isolates showed an elevation in the transcription level of *pmrK* from 1.97- to 77-fold compared to the levels obtained for our laboratory col-S wild-type strains. Moreover, 11 (55%) col-R KP isolates were found to have overexpressed *pmrC* gene from 1.67- to 15.4-fold (**Table [2](#T2){ref-type="table"}**). Our results indicated that colistin resistance significantly correlated with *pmrHFIJKLM* or *pmrCAB* upregulation. Elevated expression of studied genes was irrespective of the absence or presence of colistin (data not shown). Our results indicate that the incorporation of both aminoarabinose and PEtN into lipid A is responsible for colistin resistance with the latter being inferior to that of [L]{.smallcaps}-Ara4N substitution.

Complementation Experiments
---------------------------

Expression of wild type MgrB in isolates characterized with altered *mgrB* restored susceptibility to colistin and reduced the MIC values to levels obtained for col-S isolates (**Table [3](#T3){ref-type="table"}**). However, complementation with wild type PmrB did not alter colistin susceptibility in col-R isolates harboring mutated *pmrB*. This indicates that colistin resistance is not related to these *pmrB* alterations and modifications in loci other than *pmrB* might be involved in colistin resistance in these isolates.

###### 

MICs of colistin in *K. pneumoniae* isolates before and after complementation.

  Isolate   *mgrB* genotype        *pmrB* genotype   Complemented gene   MIC befor complementation   MIC after complementation
  --------- ---------------------- ----------------- ------------------- --------------------------- ---------------------------
  KP06      IS insertion at -60    WT                *mgrB*              64                          1
  KP12      IS insertion at +120   A246T             *mgrB*              64                          1
  KP02      IS insertion at +70    R256G             *mgrB*              32                          1
  KP01      Q30stop                L213M             *mgrB*              128                         2
                                                     *pmrB*                                          128
  KP17      C39stop                A246T             *mgrB*              128                         2
  KP03      WT                     R256G             *pmrB*              128                         128
  KP19      WT                     A246T             *pmrB*              128                         128

Discussion
==========

Colistin has recently regained significant interest constituting the major part of therapeutic regimen for management of severe infections caused by CRE ([@B17]). Despite the scarcity of colistin resistance, this anti-CRE magic bullet has begun to wane as a consequence of frequent use in clinical settings and subsequent resistance development. In our study, plasmid encoded *mcr-1, mcr-2, mcr-3, and mcr-4* genes were not detected in any of the col-R KP isolates demonstrating that resistance is mediated by chromosomally encoded mechanisms. Of 20 col-R KP isolates, 15 (75%) were identified as having an inactivated MgrB mediated by insertion of IS elements or nonsense mutations. MgrB, a small transmembrane protein with 47 amino acids mediates potent negative feedback on the PhoQ/PhoP regulatory system. It is hypothesized that critical alterations within *mgrB* found in the current study including disruption of promoter or coding region result in gene silencing or production of truncated MgrB. In fact, MgrB inactivation by any of these events results in PhoP/PhoQ activation which in turn activates the PmrA response regulator. Complementation with wild type MgrB protein restored colistin susceptibility in all col-R KP isolates with *mgrB* modifications. This verifies the resistance conferring role of *mgrB* alterations in the studied isolates. [@B20] demonstrated that insertion of IS elements (IS*5*-like, IS*Kpn13* IS*Kpn14*, IS*10R*) and Q30stop and C28stop substitutions in *mgrB* were involved in resistance to colistin in *K. pneumoniae* isolates determined by complementation assays. The Q30stop substitution has been found by several other studies ([@B18]; [@B1]) reinforcing the hypothesis that position +88 in the *mgrB* (codon 30 in protein) is a critical region which is prone to mutate upon resistance emergence. Also, [@B4] reported that *mgrB* alterations, including insertion of IS*5*-like, IS*1*-like, or IS*Kpn14* elements, non-silent point mutations, and small intragenic deletions were mediating colistin resistance in 53% of studied col-R KP isolates. All together three substitutions were found in the *pmrB* including L213M, A246T, and R256G. Complementation with wild type *pmrB* gene was not able to restore colistin susceptibility in isolates characterized with these *pmrB* alterations. Similarly, [@B7] showed that R256G substitution found in col-R KP isolates did not contribute to colistin resistance determined by site-directed mutagenesis method. Also, [@B1] suggested that A246T mutation found in the *pmrB* was not related to colistin resistance. This was because they had found this alteration in colistin susceptible isolates as well. Therefore, mechanisms of colistin resistance were not fully unraveled in five isolates characterized with *pmrB* mutations alone. A recent study showed that alterations in the newly described TCRS, CrrAB mediate colistin resistance in *K. pneumoniae* ([@B24]). [@B7] found R256G replacement in the *pmrB* as the only genetic alteration among six studied genes including *mgrB, pmrA, pmrB, phoP, phoQ*, and *pmrD* in 8 of 26 col-R KP isolates. All of these eight isolates had overexpressed *pmrHFIJKLM* operon. In an attempt to determine the exact mechanisms of decreased susceptibility to colistin in these isolates, the same authors found mutations in CrrAB TCRS. The mutations were found to be associated with overexpression of *pmrHFIJKLM* and *pmrCAB* operons in these isolates ([@B6]). Therefore, it is tempting to speculate that genetic modifications in systems other than PmrA/PmrB and PhoP/PhoQ such as CrrAB might contribute to colistin resistance in these five isolates.

Colistin resistance has been found to be associated with upregulation of *pmrHFIJKLM* and *pmrCAB* operons which result in addition of [L]{.smallcaps}-Ara4N and PEtN, to LPS, respectively. Generally, either [L]{.smallcaps}-Ara4N and/or PEtN can be added to the 4-phosphate and 1-phosphate of lipid A and both modifications decrease the anionic charge of LPS ([@B28]; [@B14]; [@B22]). However, it has been demonstrated that the LPS modification by [L]{.smallcaps}-Ara4N confers a higher level of polymyxin resistance compared to PEtN modification ([@B22]). We found a significant association between colistin resistance and upregulation of *pmrHFIJKLM* and *pmrCAB* operons. While all isolates revealed an over-expressed *pmrK*, only 55% of isolates exhibited *pmrC* upregulation implying that *pmrC*-mediated LPS modification was inferior to that of *pmrK* with regard to colistin resistance. However, one isolate (KP02) revealed partially higher expression level for *pmrC* (3.2-fold) compared to *pmrK* gene (2.5-fold). [@B12] reported that Thr157Pro substitution in PmrB was responsible for the overexpression of *pmrCAB* and *pmrHFIJKLM* operons with the *pmrC* being more overexpressed (170-fold) compared to *pmrK* (40-fold). We also observed that strains with the same mutational profile and colistin MIC values revealed distinct expression level/profile of *pmrK* or *pmrC* genes. This can be explained by the fact that determinants other than PmrB/MgrB (such as CrrAB TCRS) might contribute to regulation of operons involved in the LPS modification. Also, different MIC values between the isolates with the same genetic alterations in the studied loci can be attributed to alterations in other unknown loci or involvement of other resistance mechanisms such as increased amount of capsular polysaccharide or efflux pumps ([@B19]).

In summary, we found that MgrB alterations play major role in colistin resistance in *K. pneumoniae* isolates studied in the current work. We also found that, *pmrK* operon and therefore LPS modification with [L]{.smallcaps}-Ara4N plays prominent role in resistance conferring followed by *pmrC* operon and PEtN modification. This is the first report about molecular mechanisms of colistin resistance in *K. pneumoniae* isolates from Iran. Evaluating the role of CrrAB system in mediating colistin resistance will be the next step of this ongoing work to provide a comprehensive understanding of mechanisms involved in colistin non-susceptibility in *K. pneumoniae* isolates. In addition, multilocus sequence typing should be performed to determine whether these Iranian col-R KP isolates belong to predominant sequence types in Iran or to those, which are common in the world.
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col-R KP

:   colistin resistant *K. pneumoniae*

col-S KP

:   colistin susceptible *K. pneumoniae*

CRE

:   carbapenem-resistant *Enterobacteriaceae*

GNB

:   Gram-negative bacteria

[L]{.smallcaps}-Ara4N

:   4-amino-4-deoxy-[L]{.smallcaps}-arabinose

MDR

:   multidrug-resistant

PEtN

:   phosphoethanolamine
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